RCSI led ‘ANGIOTOX’ project selected for presentation at the American Association for the Advancement of Science (AAAS) Annual Meeting; Feb 11-15 2016 , Washington DC.

A symposium entitled ‘Improving Cancer Patient Care: Trade-Offs Between Efficacy and Toxicity’ based on work performed within the RCSI led AngioTox initiative (www.angiotox.com) has been selected by the European Commission for presentation at the prestigious AAAS Annual meeting to be held Feb 11-15 2016 in Washington DC. The recently concluded AngioTox project led by Dr Annette Byrne (Snr. Lecturer, RCSI Dept of Physiology and Medical Physics) and supported by the European Commission Industry Academia Partnerships and Pathways program, focused on the analysis of side-effects associated with the clinically approved ‘angiogenesis inhibitor’ class of cancer therapeutics, which function by inhibiting tumor blood vessel growth. Data generated within the project has provided evidence for a novel medical imaging approach for the early identification of patients at risk from cardiovascular side-effects following treatment with angiogenesis inhibitors. These data have also been presented at The New York Academy of Sciences Angiogenesis 2014 conference and the European Institute for Molecular Imaging 2014 Annual Meeting. During the AAAS conference Angiotox collaborators from the University of Pennsylvania (Dr Bonnie Ky) and VU Medical Centre Amsterdam (Dr Maria Rovithi) will also discuss new data, which will aid in the early detection of side-effects in cancer patients treated with angiogenesis inhibitors. AngioTox research partners include University College Dublin, VU Medical Centre Amsterdam, and industry partners Oncomark Ltd, Pathology Experts, Bayer Technology Services, F.Hoffman La Roche & Genentech

Congratulations to Dr. Manuela Salvucci

We are delighted to announce that submission of ”Translational application of a mathematical model of apoptotic caspase activation provides a prognostic biomarker in stage III colorectal cancer” has been selected as one of the two EACR Prize Winners and has been awarded the EACR Junior Award. This prize is €500 and free registration to attend the Anual EACR meeting this year on Thursday 25 and Friday 26 February in the Kingsley Hotel,Cork.

Congrats to Dr. Zaitun Zakaria

Congratulations to Dr.Zaitun Zakaria who was selected to give an oral presentenation at the Clinical Neuroscience Conference on the 13th of November 2015 at the RDS in Dublin. Her presentation was entitled ”Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein (IAP) antagonist Birinapant” Zakaria Z, O’Brien DF, Byrne AT, Prehn JHM.
Dr. Zakaria also presented at the 2nd Annual Neurological Surgery Symposium, RCSI, Ireland (Oral presentation, 17th July 2015) where she presented the
”Combination effect of Temozolomide and Birinapant in in vitro and in vivo intracranial GBM model” Z Zakaria, Murray D, O’Brien DF, Prehn JHM.

Dr. Zakaria also was sucessful at publishing her results in the British Journal of Cancer the paper is entitled ‘Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosisprotein antagonist birinapant’
Z Zakaria1,2, A Tivnan1, L Flanagan1, DWMurray1, M Salvucci1, B W Stringer3, B W Day3, A W Boyd3, D Ko¨gel 4, M Rehm 1, D F O’Brien2, A T Byrne1 and J H M Prehn*,1.

British Journal of Cancer (2015), 1–11 | doi: 10.1038/bjc.2015.420

Angiopredict Final Plenary Meeting

The Angiopredict consortium held its final plenary meeting in Dublin on 3 December 2015. There was a packed agenda with scientific updates and discussions about publications, presentations and exploitation. We also had an opportunity to plan for final deliverables and reports. The meeting was very productive and the team looks forward to the busy, final weeks ahead. Many thanks to project partner Oncomark for hosting

Breast-Predict hold second sucessful scientific advisory board meeting

The BREAST-PREDICT team met with members of their Scientific Advisory Board (SAB) on the 11th of September 2015 in UCD. Approximately 45 researchers met with four out of seven members of the Scientific Advisory Board to discuss key developments from year two of the centre’s research programme and to gain advice on future plans. The Scientific Advisory Board members in attendance were Prof. Robert Clarke, Georgetown University, U.S.A.; Dr. Jason Carroll, Cambridge Research Institute, U.K; Prof. Richard Kennedy, Queen’s University Belfast, U.K; and Prof. Liam Murray, also from Queen’s University Belfast.

Ten researchers presented updates on the five different workpackages, sixteen early-stage researchers displayed posters and five researchers presented oral posters to the group. This was followed by an informative discussion session in which members of the Scientific Advisory Board provided feedback to the BREAST-PREDICT team. Overall this was a very enjoyable and productive meeting and we look forward to future discussions and feedback at the end of year three.

Irish Assocaition of Pharmacologists

Congratulations to Dr Alice O’Farrell , Postdoctoral Researcher, Dept of Physiology and Medical Physics & Centre for Systems Medicine (PI Dr Annette Byrne) who won Joint First Prize for best oral presentation at the Annual Irish Association of Pharmacologists conference held at University College Cork on Oct 16th for her presentation entitled “Cardiac Metabolic Pathway Remodelling in Response to Sunitinib Malate”.

Congratulations to Meshal Alanezi

Congratulations to Meshal Alanezi (3rd Year Direct Entry Medicine student) who has been awarded the 2015 RCSI Faculty of Radiologists Fielding Medal for the best medical undergraduate radiology project in a medical school on the island of Ireland . Meshal’s project was completed as part of his “Student Selected Component (SSC)” research placement in the RCSI Laboratory of Tumour Biology & Molecular Imaging (PI Dr Annette Byrne, Graduate Entry Medicine & Department of Physiology & Medical Physics, RCSI Centre for Systems Medicine). The winning project was entitled “Pre-clinical interrogation of Regorafenib response in colorectal cancer using a multi-modality molecular imaging approach” and was supported by Science Foundation Ireland funding received by Dr Byrne in the context of the ‘Colofortell’ Career Development Award (www.colofortell.ie)